About AbOliGo
Pioneering high-performance antibody-oligonucleotide conjugates to unlock the power of multiomic analysis
Our Mission
"Our mission is to empower scientists by providing fast, reproducible, antibody-oligo conjugates (AOCs) for all."
AbOliGo is a biotechnology company developing next-generation antibody-oligonucleotide conjugates (AOCs) to unlock the power of multiomic analysis. Our proprietary conjugation platform delivers fast, reproducible, and customizable AOCs for spatial biology, proteomics, and single-cell workflows.
The Challenge: Despite over 7 million RUO antibodies available in the market, fewer than 0.1% are offered as AOCs, which will hinder scientific discovery.
AbOliGo is focused on solving this critical bottleneck through developing a conjugation platform which will deliver fast, reproducible, and customizable AOCs, transforming how researchers access these critical reagents. By enabling researchers to move seamlessly from antibody to multiomic insight, AbOliGo is redefining what's possible in biological discovery.
Technical and Commercial Execution
AbOliGo is deploying resources to achieve key milestones across innovation, manufacturing, and go-to-market efforts:
Miniaturized Process Development
Scaling down conjugation protocols to use as little as 10 µg of antibody input, allowing access to rare and costly antibodies.
Automated Manufacturing
Establishing an automated platform to increase throughput, precision, and reproducibility.
Commercial Expansion
Building a dedicated marketing and business development team to support the launch of the AOC platform.
Leadership
Dr. Brian Carpenter
CEO
Leading AbOliGo's mission to empower scientists with fast, reproducible antibody-oligo conjugates for all.
Nick Hutchings
Chairman
Founder of Absolute Antibody and Everest Biotech (both acquired by LSBio and now part of Vector Laboratories).
"AbOliGo is building a truly enabling technology platform. The company has the opportunity to reshape how researchers access high-quality AOCs at scale."
Mick Knowles
Head of Reagents
With over twenty years of conjugation expertise Mick is a named inventor on several conjugation patents (conjugation kits), and was the lead R&D scientist for Innova Biosciences.
"AbOliGo exists to remove the "black box" from antibody-oligo conjugation. In the reagent team we've are re-engineering every step of the manufacturing process from oligo selection through to QC, allowing customers to have full confidence in our products."
Dr. Nick Gee
Non-Executive Director
Former CEO of Innova Biosciences and inventor of the Lightning-Link conjugation technology (acquired by Expedeon/SYGNIS and now sold by Abcam).
"Having scaled several reagent businesses, I can say AbOliGo is on a strong trajectory. We've engineered a solution that removes friction for both research and translational labs."
Karen Padgett
Non-Executive Director
Founder & Former CEO at Novus Biologicals (acquired by Biotechne) and advisor to numerous biotech ventures.
"The combination of speed, reproducibility, and customizability is exactly what the market needs. I'm excited to help guide their commercial strategy."
Location
Headquartered in Cambridge, UK
Meditrina Building 260
Babraham Research Campus
Cambridge, CB22 3AT
Recent News
August 2025: AbOliGo successfully closed an oversubscribed seed funding round, attracting strong support from leading early-stage life sciences investors. The funding will enable AbOliGo to scale manufacturing, expand its team, and drive commercial growth.
Read the full announcement